Androgen axis in prostate cancer

Journal of Cellular Biochemistry

Volumn 99, Issue 2, 2006, Pages 373-381

  Culig, Zoran ^a   Bartsch, Georg ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Androgen; Androgen receptor; Cofactors; Prostate cancer; Therapy

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BICALUTAMIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR BLOCKING AGENT; HYDROXYFLUTAMIDE; INTERLEUKIN 6; LIGAND; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEAR RECEPTOR COACTIVATOR 2; PROTEIN P300; PROTEIN RAC 3; PROTEIN TIP60; RAS PROTEIN; SELENIUM; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; DRUG MECHANISM; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC EPIGENESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MALE; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

ANIMALIA;

EID: 33746073145     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20898     Document Type: Review

References (62)

1. Agoulnik IU, Vaid A, Bingman WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann M, Weigel NL. 2005. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65:7959-7967.
2. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. 2003. Constitutive activation of the ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981-1989.
3. Bonaccorsi L, Muratori M, Marchiani S, Forti G, Baldi E. 2006. The androgen receptor and prostate cancer invasion. Mol Cell Endocrinol 246:157-162.
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vess R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
5. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. 2005. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 65:2082-2084.
6. Cinar B, De Benedetti A, Freeman MR. 2005. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res 65:2547-2553.
7. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z. 2003. The transciptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 162:233-241.
8. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, Bartsch G, Offner F, Culig Z, Hobisch A. 2004. The androgen receptor co-activator CBP is upregulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204:159-166.
9. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
10. Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H. 1993. Mutant androgen receptor detected in an advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550.
11. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. 1994. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
12. Culig Z, Hoffmann J, Erdel M, Eder I, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. 1999. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242-251.
13. Debes JD, Schmidt LJ, Huang H, Tindall DJ. 2002. p300 mediates interleukin-6-dependent transactivation of the androgen receptor. Cancer Res 62:5632-5636.
14. Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. 2005. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65:5965-5973.
15. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. 2000. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 7:997-1007.
16. Gao M, Ossowski L, Ferrari AC. 1999. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 179:336-346.
17. Giri D, Ozen M, Ittmann M. 2001. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159:2159-2165.
18. Godoy-Tundidor S, Hobisch A, Pfeil K, Bartsch G, Culig Z. 2002. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 8:2356-2361.
19. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319.
20. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, Wilson EM. 2004. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279:7119-7130.
21. Halkido K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, Leung HY, Neal DE, Robson CN. 2003. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22:2466-2477.
22. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, DeMayo FJ, Tilley WD, Greenberg NM. 2005. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102:1151-1156.
23. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. 2003. Novel mutations of androgen receptor-A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-153.
24. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. 1995. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068-3072.
25. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. 1998. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640-4645.
26. Hobisch A, Fiechtl M, Sandahl-Sorensen B, Godoy-Tundidor S, Artner-Dworzak E, Ramoner R, Bartsch G, Culig Z. 2004. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression. Prostate 59:401-408.
27. Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z. 2006. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate 66:413-420.
28. Huggins C, Hodges CV. 1941. Studies on prostatic cancer: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297.
29. Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I, Helin HJ, Janne OA, Vihinen M, Palvim JJ, Koivisto PA. 2002. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 82:1591-1598.
30. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. 1997. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 3:2507-2511.
31. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choo A, Reznikoff CR, Bova GS, Friedl A, Jarrard DF. 2000. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 60:3623-3630.
32. Kokontis J, Takakura K, Hay N, Liao S. 1994. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566-1573.
33. Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S. 2005. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 65:287-298.
34. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. 2004. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145:2941-2949.
35. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C. 2004. Suppression vs induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278:50902-50907.
36. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL, Vessella RL, Palvimo JJ, Visakorpi T. 2004. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 10:1032-1040.
37. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE. 2005. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65:3404-3409.
38. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, Eastham J, Weigel NL, Lamb DJ. 2000. Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949.
39. Matsuda T, Junicho A, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A. 2001. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 283:179-187.
40. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. 2004. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517-527.
41. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. 2005. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436-439.
42. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varrichio L, Ciociola A, Auricchio F. 2005. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: Steroid antagonist action. Cancer Res 65:10585-10593.
43. Mills IG, Gaughan L, Robson CN, Ross T, McCracken S, Kelly J, Neal DE. 2005. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. J Cell Biol 170:191-200.
44. Mohler JL, Gregory CW, Ford OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS. 2004. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448.
45. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER. 1992. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323.
46. Nishimura K, Ting HJ, Harada Y, Tokizane T. Nonomura N, Kang HY, Chang HC, Yeh S, Miyamoto H, Shin M, Aozasa K, Okuyama A, Chang C. 2003. Modulation of androgen receptor transactivation by gelsolin: A newly identified androgen receptor coregulator. Cancer Res 63:4888-4894.
47. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. 2000. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992-1995.
48. Quarmby VE, Beckman WCJ, Cooke DB, Lubahn DB, Joseph DR, Wilson EM, French FS. 1990. Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 50:735-739.
49. Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave ME, Rennie PS. 2006. Cyclin G-associated kinase: A novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer 118:1108-1119.
50. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P. Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. 2004. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279:19191-19200.
51. Swinnen JV, van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. 1996. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137:4468-4474.
52. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515.
53. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY, Simons JW. 1995. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 45:542-549.
54. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. 2002. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-38094.
55. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. 2004. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 64:7156-7168.
56. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO. 1990. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 17:534-540.
57. Watson PA, Ellwood-Yen K, King JC, Wongvipa J, Lebeau MM, Sawyers CL. 2005. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 65:11565-11571.
58. Yeh S, Chang C. 1996. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517-5521.
59. Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O. 2005. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65:9611-9616.
60. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. 2000. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703-706.
61. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LWK. 1996. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93:15152-15157.
62. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdeme H, Ittmann M, Tsai SY, Tsai MJ. 2005. SRC-3 is required for prostate cancer proliferation and survival. Cancer Res 65:7976-7983.